Glioblastoma (GBM) is the most common primary brain tumor in adults, and the most lethal
form of glioma, characterized by variable histopathology, aggressiveness and poor clinical …

Simple Summary Despite advances in cancer treatment, difficult-to-treat tumor subtypes
remain a challenge. New multidisciplinary approaches can help overcome current obstacles …

Based on the findings in recent years, we summarize the therapeutic potential of vorinostat
(VOR), the first approved histone deacetylase (HDAC) inhibitor, in disorders of brain, and …

Medical nanotechnology is surfacing as a challenging arena covering new biomedical
applications, such as drug delivery, treatment, nano diagnosis, controlled drug release …

Gene expression at the transcriptional level is altered by epigenetic modifications such as
DNA methylation, histone methylation, and acetylation, which can upregulate, downregulate …

Chemoresistance is a significant clinical challenge, limiting the drug response in cancer.
Several mechanisms associated with drug resistance have been characterized, and the role …

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as APO2L, has
emerged as a highly potential anticancer agent because of its capacity to effectively trigger …

Introduction Cancer is a major public health problem with over 19 million cases reported in
2020. Similarly to humans, dogs are also largely affected by cancer, with non-Hodgkin's …

Histone deacetylase inhibitors (HDACi) are cancer therapeutics that operate at the
epigenetic level and which have recently gained wide attention. However, the applications …

The most eminent research of the 21st century whirls around the epigenetic and the
variability of DNA sequences in humans. The reciprocity between the epigenetic changes …